摘要
目的探讨非小细胞肺癌(NSCLC)组织表达切除修复交叉互补基因1(ERCC1)与顺铂耐药的相关性。方法以2010年4月-2013年7月江西省肿瘤医院收治的79例NSCLC患者作为研究对象,采用免疫组化法检测上述研究对象新鲜肿瘤组织标本的ERCC1表达水平,给予所有研究对象2个疗程的化疗,化疗方案为长春瑞滨联合顺铂。化疗2个周期后,采用《实体瘤的疗效评价标准》(RECIST)进行疗效评价。结果 (1)79例NSCLC患者,37例ERCC1呈阳性表达,42例ERCC1呈阴性表达。(2)ERCC1阳性表达组与ERCC1阴性表达组之间的性别、年龄、病理类型、TNM分期、吸烟史相比差异无统计学意义(P>0.05)。ERCC1阴性表达组的化疗疗效显著优于ERCC1阳性表达组,两者相比差异有统计学意义(P<0.05)。结论 NSCLC患者检测ERCC1有助于预测患者对顺铂的耐药性。
Objective To investigate the relationship between excision repair cross-complementing gene 1 （ERCC1） expression and Cisplatin resistance in patients with non-small cell lung cancer （NSCLC）. Methods 79 cases of NSCLC admitted into the Jiangxi provincial tumor hospital from April 2010 to July 2013 were selected as the objects of study, and the level of expression of ERCC1 in fresh tumor tissue from these patients were determined by immunohistochemical method. All patients received 2 courses of chemotherapy,and the scheme was Vinorelbine plus Cisplatin. Results （1）Among 79 cases of NSCLC,37 cases were ERCC1-positive,while other 42 cases were ERCC1-negative. （2）No significant differences were found in the gender,age,pathological type,TNM stage and history of smoking between ERCC1-positive group and ERCC1-negative group （P〉0.05）. （3）After 2 courses of chemotherapy,the curative effect in all patients were evaluated using response evaluation criteria in solid Tumors （RECIST）. The curative effect in ERCC1-negative group was significantly better than that in ERCC1-positive group （P〈0.05）. Conclusion The determination of ERCC1 in patients with NSCLC contributes to predicting the cisplatin resistance.
出处
《江西医药》
CAS
2014年第3期194-196,共3页
Jiangxi Medical Journal
基金
江西省卫生厅课题(20070058)
关键词
非小细胞肺癌
切除修复交叉互补基因1
顺铂
Non-small cell lung cancer
Excision repair cross-complementing gene 1
Cisplatin
